Hyun Joon Lee
CEO
N
Neuronity
Neuronity develops innovative therapies focused on promoting central nervous system immunity to address neurological disorders. The company's science centers on boosting healthy immune cells within the aged nervous system. This approach aims to prevent the progression of neurodegenerative diseases.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$780KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Aging reduces immune activity in the brain, contributing to the development and progression of neurodegenerative diseases. Current treatment options for these diseases often fail to address the underlying immune dysfunction in the central nervous system.
Solution
Neuronity is developing first-in-class immunotherapies designed to enhance the immune response within the central nervous system, specifically targeting age-related neurodegenerative diseases. Their approach focuses on boosting the activity of healthy immune cells in the aged nervous system to prevent or slow the progression of diseases like Parkinson's disease. By modulating the neuroimmune environment, Neuronity aims to provide a novel therapeutic strategy for combating these debilitating conditions.
Target Audience
The primary target audience includes individuals at risk of or affected by age-related neurodegenerative diseases, as well as clinicians and researchers focused on neuroimmunology and novel therapeutic interventions for these conditions.
Features
- Focus on promoting immunity of the central nervous system.
- Development of therapies to boost healthy immune cells in the aged nervous system.
- Targeting of age-related neurodegenerative diseases.